Member Info for Moneymunch

Presumably there could be significant potential development news from the US Army, which would obviously be a great addition and huge interest to any BIO considering a RTO. Gla :-)

24/10/19

RNS Number: 9200Q Motif Bio PLC, 24 October 2019

Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with the Walter Reed Army Institute of Research (WRAIR) to conduct pre-clinical testing to evaluate novel combinations with iclaprim to improve safety and efficacy administered by a novel enhanced aerosol technology.

htTps://adisinsight.springer.com/drugs/800018080

What sort of value would be attributed to a self administered hand held inhaler, effective for the treatment of sevre lung conditions associated with Covid-19???

It's not just the Covid-19 market that a self administered hand held inhaler combined with iclaprim could be of therapeutic benefit...Gl and fingers crossed for a suspension of shares this coming week, Monday preferably. Presumably anyone betting short would have their position locked in as well, until the RTO goes through to listing. ;-)6/6/19"We continue to believe that iclaprim has the potential to be an important new treatment option for hospitalised patients with ABSSSI and potentially also in patients with hospital-acquired bacterial pneumonia, including ventilator-associated bacterial pneumonia. In addition, we are exploring the use of iclaprim in other disease areas, including orphan indications such as Staphylococcus aureus lung infections in patients with cystic fibrosis and in ophthalmology, as evidenced by recently announced collaborative agreements."

Targeting STAT3

SFX-01 is inspired by a natural compound which is found in cruciferous vegetables such as rocket, broccoli and kale.

In a recent clinical trial, called STEM, it was found to delay the disease getting worse in women with secondary breast cancer whose disease had already developed resistance to hormone therapy. In the trial, 25% of participants benefitted from the addition of SFX-01 to hormone therapy, but the reason this worked wasn’t known until now.

In this new research, the team found that SFX-01 blocks an important chain of reactions, called the STAT3 signalling pathway, in breast cancer cells. As a result, it reduced the ability of breast cancer cells to form tumours in mice.

The detailed understanding of how this drug works will now allow researchers to find when it’s most effective. They hope that in future it could be added to hormone therapies from the outset of treatment to increase their effectiveness in women with primary breast cancer.

Co-author Dr Bruno Simões, Research Fellow at the University of Manchester, further explained their findings:

‘We are excited by our findings that combining standard hormone therapies with SFX-01 could improve treatment of some breast cancer patients by reversing resistance driven by the STAT3 signalling pathway.’

Simon added: ‘This important discovery reveals exactly how SFX-01 can help overcome hormone therapy resistance. We hope it could now open the door to it being used from the outset of treatment, to prevent resistance from developing in the first place.’
Fine-tuning the results

Using these findings, the researchers’ next steps are to understand why some people’s tumours are more sensitive to SFX-01. They also want to know if looking at the activity of the STAT3 signalling pathway could provide a new test to determine who would benefit the most from the new drug.

‘With the success of the recent clinical trial in secondary breast cancer, we hope that further studies will now help to identify which patients may benefit the most from this drug so that it could soon reach the clinic,’ said Bruno.

Simon added: ‘We look forward to results of further trials to fully understand who is likely to benefit most and at what stage of treatment it should be added to hormone therapy to give patients the best chance of survival.’

This study was presented at the UKIBCS.

https://breastcancernow.org/about-us/news-personal-stories/novel-drug-inspired-cruciferous-vegetables-could-reverse-drug-resistance-in-oestrogen-receptor-positive-breast-cancer

Co-author of the study Dr Bruno Simões, research fellow at the University of Manchester, said: “Oestrogen receptor positive breast cancer is the most common breast cancer. These cancers frequently develop resistance to hormone therapies, which is a major clinical problem that we are working to address.

“We are excited by our findings that combining standard hormone therapies with SFX-01 could improve treatment of some breast cancer patients by reversing resistance driven by the STAT3 signalling pathway.

“With the success of the recent clinical trial in secondary breast cancer, we hope that further studies will now help to identify which patients may benefit the most from this drug so that it could soon reach the clinic.”

Dr Simon Vincent, director of Research at Breast Cancer Now, which helped to fund the study, said: “It’s really exciting that SFX-01 could in future help to improve the effectiveness of hormone therapies and prevent or treat the return of breast cancer. While hormone therapy is effective for most women, around a third still see their breast cancer return and we urgently need to find new ways to tackle and prevent drug resistance.

“This important discovery reveals exactly how SFX-01 can help overcome hormone therapy resistance and we hope it could now open the door to it being used from the outset of treatment, to prevent resistance from developing in the first place.”

Broccoli-based' drug could help treat breast cancer

29 January 2020

A new drug based on a compound found in cruciferous vegetables could improve the effectiveness of breast cancer hormone therapies, new research suggests.

Scientists at the University of Manchester found that the drug SFX-01 could reverse or potentially prevent resistance to hormone therapies by blocking a chain of reactions within cancer cells known as STAT3.

Up to 80% of breast cancer cases are known as oestrogen receptor (ER) positive breast cancer, since the disease’s growth is encouraged by the oestrogen hormone.

Hormone therapy can be very effective in reducing the risk of recurrence, though it’s thought around a third of patients with ER positive breast cancer see their disease return within 15 years, with some cases being attributable to patients developing resistance to treatment.

The team in Manchester assessed how SFX-01 worked by itself, as well as in combination with the hormone therapies tamoxifen and fulvestrant. The drug was tested both in patient samples and mice to see how it can be used to treat breast cancer. They found that SFX-01 reduced the ability of breast cancer stem cells to form tumours in mice, while also reducing the ability of breast cancer cells to form secondary tumours in the mice’s lungs.

The researchers also examined gene activity levels within the breast cancer stem cells from hormone therapy-resistant tumour samples from patients, discovering how cancer stem cells relied heavily on the STAT3 signalling pathway. STAT3 is able to become active when hormone therapy is used and ultimately lead to treatment resistance. However, the researchers discovered that SFX-01 was able to block the STAT3 signalling pathway and reverse the effects that may lead to hormone therapy resistance.

The drug - developed by UK company Evgen Pharma - has previously shown promise in a phase II trial as a treatment for secondary breast cancer that is already resistant to hormone therapy. That trial showed that SFX-01 was able to delay the progression of incurable secondary breast cancer in women who had already developed resistance to hormone therapy.

The drug was inspired by the natural compound sulforaphane, which is abundant in vegetables such as rocket, broccoli and kale.

The scientists in Manchester now hope that the drug could be added tamoxifen or aromatase inhibitors to increase those drugs’ effectiveness in patients with primary breast cancer. More so, the team hopes that SFX-01 could be used as a new option to treat secondary breast cancer.

The study results were presented at the UK Interdisciplinary Breast Cancer Symposium, hosted by the charity, Breast Cancer Now, in Birmingham.

Co-author of the study Dr Bruno Simões, research fellow at the University of Manchester, said: “Oestrogen receptor positive breast cancer is the most common breast cancer. These cancers frequently develop resistance to hormone therapies, which is

Lol,Goodnight and Good Luck, although I personally think you should have held on a while longer, at least until next week or so.....News of the new CEO could have a significant lift along with any update on proceedings . On and Up!!! :-)

Lol, alas not and unfortunately missed that one , the only thing darker in my Malvern is the Whiskey...:-)))

Should have bought some Malvern, Top Riser No1 today.;-)

Ps EVG's turn soon...Gla :-)

Every chance of news after the long weekend. Gla ;-)

0  5 0

One important point to make is that when RTO news is confirmed, those not in will be locked out until listing. The shares will be temporarily suspended until official listing day, as is the case with every RTO, and unlike the majority of RTO's , if Motif's RTO target is a cutting edge Healthcare Bio involved in the development of Covid-19 treatments etc, then the market cap of the new company could be multiples of Motif's current market cap,and could rise significantly on listing as the demand for shares on listing day is likely to be considerable. Hold on tight and enjoy the ride, otherwise miss out on the potential stellar Upside....Gla Holders...RTO news could drop at anytime!!! ;-)

 0

Just a thought, I assume anyone betting short would be locked in along with their short position on the stock, on RTO confirmation, while the shares are temporarily suspended until official listing day. Now that could be the ruination of a few...with any luck. Gla holders....RTO news could drop at anytime. ;-)

One important point to make is that when RTO news is confirmed, those not in will be locked out until listing. The shares will be temporarily suspended until official listing day, as is the case with every RTO, and unlike the majority of RTO's , if Motif's RTO target is a cutting edge Healthcare Bio involved in the development of Covid-19 treatments etc, then the market cap of the new company could be multiples of Motif's current market cap,and could rise significantly on listing as the demand for shares on listing day is likely to be considerable. Hold on tight and enjoy the ride, otherwise miss out on the potential stellar Upside....Gla Holders....RTO news could drop at anytime!!! ;-)

Ditto, although i've had a glass or two of Malvern Water, can't remember if it was still or sparkling but went down well at the time. Gl ;-)

Motif have now got enough cash in the bank to ensure a successful RTO, they are in discussions with several Healthcare Bio targets and have appointed the high profile and highly respected Chris Wardhaugh to the BoD, who definitley wouldn't have joined the board unless he was confident of a successful conclusion, and no doubt whoever the RTO target is , Lamellar could be highly likely, they will be motivated by ilcaprim's phase 11/111 status and the time and money that will be saved given that it can be taken straight into patient trials, and very likely Covid-19 patient trials...the UPside and market cap of the RTO target could be considerable from this current bargain low. Gla ;-)

4/5/20

Christopher (Chris) Wardhaugh is appointed as a Non-Executive Director

Chris is currently a Non-Executive Director of Altair Medical Limited and Lamellar Biomedical Limited, both based in Scotland. Chris is also Chief Business Officer of MGB Biopharma Limited, a clinical-stage antibiotic company and is the founder of Sercader Limited, a life sciences advisory firm.

Chris has over 28 years' experience in life sciences with international experience across large and small companies, all stages of development and commercialisation of companies including preclinical and clinical development, product launches throughout Europe and the United States, M&A and corporate development. Chris has an impressive transaction history working on deals including product licensing, IPOs and both Angel and VC investments.

Commenting, Bruce Williams, Chairman of Motif Bio, said: "We welcome Chris to the Board as we focus on sourcing an appropriate reverse takeover candidate for Motif Bio. We believe that the Company will benefit from Chris's breadth of knowledge and transactional experience and we will provide shareholders with further updates in due course."

8/4/20

Lamellar Biomedical Launches Program Designed to Prevent the Severe Respiratory Effects of COVID-19, Using its Unique LAMELLASOMEâ„¢ Technology

....................

A LAMELLASOMEâ„¢ nebulised treatment used at the early stages of COVID-19, in hospital or the community, could reduce the damaging and often fatal inflammatory response known as Acute Respiratory Distress Syndrome (ARDS) seen in patients. This early intervention has the potential to inhibit fibroproliferative changes during ARDS, markedly reducing severity, mortality and lowering the significant burden placed on the healthcare system.

The time between onset of symptoms of SARS-CoV2 infection and progression to more severe clinical manifestations of COVID-19 such as viral pneumonia and ARDS, is thought to be between 5 – 8 days. Inhaled LAMELLASOME™ treatment administered during this period has the potential to halt or reduce the severity of the disease progression of COVID-19 patients to requiring scarce critical care resource.

Lamellar has strong pre-clinical evidence of inhaled LAMELLASOME™'s protective nature. In a large animal in‑vivo model of radiation-induced lung injury, designed to replicate the pathology found in the injured lung, which is representative of COVID-19 patient pathology, inhaled LAMELLASOME™ treatment protected lung cells and tissues from injury, pneumonitis and fibroproliferation/fibrosis at the alveolar/capillary membrane.

Dr Duncan Moore, Chairman of Lamellar, said: "In the past few weeks we have seen the terrible consequences COVID-19 can have on the respiratory function, particularly on vulnerable patient populations. We believe that that the inherent attributes of LAMELLASOMEâ„¢ are extremely well suited to be a potential approach to preventing the onset of the serious respiratory symptoms seen in COVID-19 patients. Lamellar is focused on treating complex lung disorders and we believe that our Lamellasome formulations could make an important difference to patients and healthcare providers globally."

Dr Nik Hirani, Reader in Respiratory Medicine and Associate Medical Director in Lothian and Former chair of NICE Thoracic Interstitial Lung Disease guideline committee, said: "Lamellar has very convincing data demonstrating strong in-vivo efficacy for Lamellasome formulations in a model relevant to pneumonitis, lung injury and ARDS. I have been following the development of LAMELLASOMEâ„¢ technology and its development as a respiratory therapeutic over the past few years, and I believe it has real potential to manage the inflammatory respiratory symptoms seen in patients infected with SARS-CoV2."

https://www.ptcommunity.com/wire/lamellar-biomedical-launches-program-designed-prevent-severe-respiratory-effects-covid-19-using

6/6/19

"We continue to believe that iclaprim has the potential to be an important new treatment option for hospitalised patients with ABSSSI and potentially also in patients with hospital-acquired bacterial pneumonia, including ventilator-associated bacterial pneumonia. In addition, we are exploring the use of iclaprim in other disease areas, including orphan indications such as Staphylococcus aureus lung infections in patients with cystic fibrosis and in ophthalmology, as evidenced by recently announced collaborative agreements.

1/5/19

Motif Bio Signs Agreement with Lamellar Biomedical

Evaluation of Iclaprim in Combination with LMS-611 for Cystic Fibrosis Lung Infections

Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with Lamellar Biomedical Limited (Lamellar) under which Motif Bio will conduct an in vivo pre-clinical study evaluating iclaprim in combination with Lamellar's patented LAMELLASOME(TM) technology.

Iclaprim has been granted U.S. orphan drug designation for Staphylococcus aureus pneumonia in patients with Cystic Fibrosis (CF). Lamellar's LAMELLASOME(TM) candidate LMS-611, which has mucokinetic (mucus clearing) properties, has demonstrated antibiotic potentiation (the enhancement of certain properties of antibiotics) and has European orphan drug designation for CF.

The companies believe that, based on pre-clinical data with the two individual components, the combination could be a promising potential treatment for lung infections in patients with CF.

Dr. Graham Lumsden, Chief Executive Officer of Motif Bio, said: "We have been looking for a way to optimise the development of iclaprim in patients with CF. We are excited about the preliminary data we have seen with Lamellar's technology and look forward to evaluating it in combination with iclaprim."

Dr. Alex McLean, Chief Executive Officer of Lamellar Biomedical, said: "CF is a key area of interest for Lamellar. We are delighted to announce this partnership with Motif Bio, which will evaluate the antibiotic potentiation properties of our LAMELLASOME(TM) technology in combination with iclaprim. This collaboration augments our own work in this orphan indication, which is focused on a novel nucleic acid-based therapeutic, as we strive to develop a range of highly effective treatment options for patients with CF."

Motif fully funded to ensure successful RTO, the highly respected Chris Wardhaugh appointed to BoD at the most crucial time in proceedings, and their lead drug iclaprim ready to go straight into patient trials and strongly believed to be of great benefit in Covid-19 treatment....This will go big time in due course......Big bounce on the cards Gla ;-)

News expected soon on new CEO, and updates on existing and new developments could drop at anytime, including the high chance of SFX-01 evaluation for Covid-19 imho. Gla Holders ;-)

5/12/19

Memorandum of Understanding with The University of Dundee

Evgen Pharma (AIM: EVG) a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces it has entered into a Memorandum of Understanding with the The University of Dundee ("The University") to advance SFX-01 towards a clinical trial in non-alcoholic steatohepatitis ("NASH") and liver fibrosis. Evgen has agreed to supply SFX-01 to support a potential future clinical trial led by John Dillon, Professor of Hepatology and Gastrenterology in the University's School of Medicine.

John Dillon, Professor of Hepatology and Gastrenterology at the University of Dundee's the School of Medicine said: "We are delighted that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with NASH. Oxidative stress is pivotal to the development of NASH and our research suggests that activation of the Nrf2 pathway, which in turn reduces oxidative stress, can reverse the pathology."

6/2/20

University of Manchester collaboration discovery

Gene signature identified which may determine response to SFX-01 in ER+ breast cancer treatment

Evgen closer to predicting which patients are most likely to benefit from breast cancer drug

Steve Franklin, CEO of Evgen Pharma, said: "This latest data from an eight-year collaboration with Manchester University, and the forthcoming publication, are very positive developments for both the design of future clinical trials and for supporting business development activity with potential partners. The University of Manchester have been tremendous collaborators and we would like to thank them for their continued commitment and enthusiasm.

13/2/20

University of Rochester Collaboration

Evgen Pharma (Evgen) and The University of Rochester School of Medicine and Dentistry have entered into a Memorandum of Understanding to advance SFX-01 towards a clinical trial in chronic kidney disease (CKD).

Thu Le, Professor of Medicine, and Chief of the Division of Nephrology at the University of Rochester Medical Center said: "We are pleased that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with CKD. Increased oxidative stress is a major molecular underpinning of CKD progression and our research suggests that patients with the GSTM1 null allele may particularly benefit from sulforaphane treatment via SFX-01 dosing."

Dr Stephen Franklin, CEO of Evgen Pharma, commented:

"We are delighted to be supporting the work of such a respected team and prestigious university. We very much hope the proposed trial will generate data demonstrating that SFX-01 could potentially improve the lives of patients suffering from CKD."

Some nice chunky buys at close....all bodes well as Sulforaphane's profile appears to be increasing, including a potential treatment for Covid-19....Gla :-)